Amarin's Off-Label Victory Opens Door To More Injury Claims
Amarin Pharma Inc.'s landmark win in its New York federal suit against the U.S. Food and Drug Administration upholds drugmakers' right to truthfully promote their products' unapproved uses, but attorneys say...To view the full article, register now.
Already a subscriber? Click here to view full article